These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3020591)

  • 41. On the multiplicity of platelet prostaglandin receptors. II. The use of N-0164 for distinguishing the loci of action for PGI2, PGD2, PGE2 and hydantoin analogs.
    Tynan SS; Andersen NH; Wills MT; Harker LA; Hanson SR
    Prostaglandins; 1984 May; 27(5):683-96. PubMed ID: 6087417
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets.
    Whittle BJ; Hamid S; Lidbury P; Rosam AC
    Adv Exp Med Biol; 1985; 192():109-25. PubMed ID: 2871707
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
    Zahavi M; Zahavi J; Kakkar VV
    Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of PGD2, PGE1, and PGI2-analogues on PGDF-release and aggregation of human gelfiltered platelets.
    Stürzebecher S; Nieuweboer B; Matthes S; Schillinger E
    Prog Clin Biol Res; 1989; 301():365-9. PubMed ID: 2477855
    [No Abstract]   [Full Text] [Related]  

  • 45. Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets.
    Fortini A; Modesti PA; Abbate R; Gensini GF; Neri Serneri GG
    Thromb Res; 1985 Nov; 40(3):319-28. PubMed ID: 3001968
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synergism between PGE1-metabolites(13,14-dihydro-prostaglandin E1, 15-keto prostaglandin E1, 15-keto-13,14-dihydro-prostaglandin E1) and nitric oxide (NO) on platelet aggregation.
    Katzenschlager R; Weiss K; Rogatti W; Peskar BA; Sinzinger H
    Prostaglandins Leukot Essent Fatty Acids; 1992 Mar; 45(3):207-10. PubMed ID: 1589447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Do human platelets have opiate receptors?
    Reches A; Eldor A; Vogel Z; Salomon Y
    Nature; 1980 Nov; 288(5789):382-3. PubMed ID: 6253832
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245 C, with high affinity and selectivity for PGD2 receptors.
    Town MH; Casals-Stenzel J; Schillinger E
    Prostaglandins; 1983 Jan; 25(1):13-28. PubMed ID: 6302737
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV; Aiken JW; Shebuski RJ; Gorman RR
    Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impaired platelet prostacyclin receptor activity: a monozygotic twin study discordant for spinal cord injury.
    Kahn N; Sinha A; Bauman W
    Clin Physiol; 2001 Jan; 21(1):60-6. PubMed ID: 11168298
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of prostaglandin D2 (PGD2) as an anticoagulative agent for haemodialysis in comparison with prostaglandin E1 (PGE1).
    Nakagawa S; Matsui N; Akiba T; Shinoda T; Fukudome Y; Ozawa K; Baba M; Nakanishi T; Takeuchi J
    Proc Eur Dial Transplant Assoc; 1981; 18():117-21. PubMed ID: 7036145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Platelet aggregation. II. Adenyl cyclase, prostaglandin E1, and calcium.
    Vigdahl RL; Marquis NR; Tavormina PA
    Biochem Biophys Res Commun; 1969 Oct; 37(3):409-15. PubMed ID: 4310667
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation.
    Seiler S; Brassard CL; Arnold AJ; Meanwell NA; Fleming JS; Keely SL
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1021-6. PubMed ID: 2175792
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cyclic AMP turnover in response to prostaglandins in intact platelets: evidence for separate stimulatory and inhibitory prostaglandin receptors.
    Ashby B
    Second Messengers Phosphoproteins; 1988; 12(1):45-57. PubMed ID: 2848122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids.
    Sharif NA; Crider JY; Xu SX; Williams GW
    J Pharmacol Exp Ther; 2000 May; 293(2):321-8. PubMed ID: 10772998
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of adenosine diphosphate-induced intravascular aggregation of rat platelets in vivo by 6-oxo-prostaglandin E1.
    Oyekan AO; Botting JH
    Prostaglandins; 1987 Sep; 34(3):359-66. PubMed ID: 3324168
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The antagonism of prostaglandins I2, E1 and D2 by prostaglandin E2 in human platelets.
    Bonne C; Martin B; Watada M; Regnault F
    Thromb Res; 1981 Jan 1-15; 21(1-2):13-22. PubMed ID: 6262942
    [No Abstract]   [Full Text] [Related]  

  • 58. Effects of TRK-100, a stable prostacyclin analogue, on regulation of cyclic AMP metabolism in platelets.
    Nogimori K; Kajikawa N; Nishio S; Yajima M
    Prostaglandins; 1989 Feb; 37(2):205-12. PubMed ID: 2543034
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Platelet prostaglandin E1 hyposensitivity in schizophrenia: reduction of prostaglandin E1- or forskolin-stimulated cyclic AMP response in platelets.
    Ofuji M; Kaiya H; Nozaki M; Tsurumi K
    Life Sci; 1989; 45(22):2135-40. PubMed ID: 2557518
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SQ-27986 inhibition of platelet aggregation is mediated through activation of platelet prostaglandin D2 receptors.
    Seiler S; Brassard CL; Federici ME
    Prostaglandins; 1990 Aug; 40(2):119-30. PubMed ID: 2171039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.